Navigation Links
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Date:6/8/2009

Analysis of Subjects with Moderately Severe Diabetic Neuropathy Shows Statistically Significant Improvement in Multiple Quantitative Neurological Endpoints

RICHMOND, Calif., June 8 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of as yet unreleased positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), held in New Orleans, LA, from June 5 to 9, 2009. Data from Sangamo's SB-509-601 and SB-509-701A Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

"We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health," stated Dale Ando, M.D., Sangamo's Vice President of Therapeutic Development and Chief Medical Officer. "Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population."

"SB-509 is the first drug candidate of its type designed to harness the body's own regenerative potential to address DN, a significant complication for diabetic patients," stated Alan Lewis, Ph.D., President and Chief
'/>"/>

SOURCE Sangamo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
2. Sangamo BioSciences Reports First Quarter 2009 Financial Results
3. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
6. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
8. Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
9. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... the year for the latest science in the field. ... Care Association (ACCA) of the European Society of Cardiology ... , Monday 16 September 2014 Sophia Antipolis, France ... dealing with acute problems in need of urgent care ... The scientific programme is available here . , ...
(Date:9/16/2014)... This news release is available in French . ... of a healthy diet and dietary guidelines recommend the daily ... yogurt, cheese, cream and butter. , It,s well ... bones, but new research has shown that dairy consumption may ... risk of metabolic diseases such as obesity and type 2 ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 According ... NFL player David Wilson has retired after aggravating a neck ... disc, and was then discovered to have spinal stenosis as ... affects many adults and can lead to symptoms such as ... could play again after surgery to repair the disc, but ...
(Date:9/16/2014)... NEW YORK (PRWEB) September 16, 2014 Today ... announced that its annual “Festive Evening of Song,” featuring luminary ... will take place on Monday, September 29, 2014 at the ... in Tarrytown, New York. The FSH Society is proud to ... event aimed at raising funds for FSHD research. , FSHD, ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 According to ... leading global authority in medical device market research, the ... over $750 million in the U.S . and ... initial PEG placement kits, PEG replacement tubes, DPEJ tubes, ... segmented into low-profile balloon tubes, low-profile non-balloon tubes, nasogastric ...
Breaking Medicine News(10 mins):Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 2Health News:ACCA congress: Ensuring a rapid response to cardiac emergencies 3Health News:More cheese, please! News study shows dairy is good for your metabolic health 2Health News:NFL Injuries Put Spotlight on Spinal Health 2Health News:NFL Injuries Put Spotlight on Spinal Health 3Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3
... Dana-Farber Cancer Institute in Boston, Massachusetts has come out ... monitored, prescribed and// coordinated in a better way. ... the institutes that participated in the research, Dr Lawrence ... the importance of forging a consensus in the oncology ...
... Canadian Institute of Health Research, in collaboration with Heart ... and women react// differently to medications for their heart ... by Canadian GENESIS project, men's ailing hearts respond differently ... Angiograms, which are usually effective in pinpointing heart problems ...
... the onset of dementia”, claims a research report. This study ... Toronto, Canada on 184 elderly patients. ... remaining spoke only one language. The average age in the ... was 71.4 in the other group. The study had considered ...
... you looking for simple ways to improve your heart health? ... or sprinkled throughout your day, may be one easy and// ... almonds continues to show why including a handful of almonds ... a look at what they are finding. ,Almonds ...
... specific health care should be provided for British Muslims. Professor ... the key for better health for Muslims in United Kingdom. ... Journal, professor reiterates the need for academicians, doctors and policy ... in the existing system. ,A provision for ...
... heart disease is a two-way street: Poor sleep can ... sleep, reports the January 2007// issue of the Harvard ... with high blood pressure, atherosclerosis, heart failure, heart attack ... these together may be inflammation, the body’s response to ...
Cached Medicine News:Health News:Watchdog to Be Set on Oral Chemotherapy, Warns Experts 2Health News:Be True to Your Heart With a Handful of Almonds 2Health News:Be True to Your Heart With a Handful of Almonds 3
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
(Date:9/16/2014)... 2014  Eli Lilly and Company (NYSE: ... agreement to co-develop and commercialize AZD3293, an oral ... development as a potential treatment for Alzheimer,s disease. ... characterized by the accumulation of amyloid plaque in ... the development of beta-amyloid. Inhibiting BACE is expected ...
(Date:9/15/2014)... WHIPPANY, N.J. , Sept. 16, 2014 /PRNewswire/ ... based in Espoo, Finland , ... III trial with ODM-201, an investigational oral androgen ... ARAMIS, evaluates ODM-201 in men with castration-resistant prostate ... levels and no detectable metastases. The trial is ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... and KOS, Greece, June 29, 2007 /PRNewswire/ --,The ... treated patients on REVLIMID (lenalidomide) plus the,steroid dexamethasone ... The data are pooled from two large randomized,controlled ... patients,from nearly 100 clinical sites worldwide. These updated ...
... at the 11th International Myeloma Workshop ... of perifosine in,combination with bortezomib, dexamethasone ... relapsed/refractory multiple,myeloma, and as a single ... NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
Inquire...
... at the point of care: , Only 120 ... only 70 L of whole blood (all parameters except ... of sensor cassette , safePICO mixer ensures thorough and ... in 7 seconds) * Not ...
Medicine Products: